copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Marinus Pharmaceuticals, Inc. - News Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC . . . Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders The Company’s product, ZTALMY ® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U S in 2022
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and . . . Marinus has decided to complete enrollment in the RAISE trial at approximately 100 patients with topline results expected in the summer of 2024 Those results will be used to determine whether to continue development of IV ganaxolone
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial . . . Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders The Company’s product, ZTALMY ® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the U S in 2022
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for . . . Marinus expects to initiate a multiple ascending dose study of a second generation ganaxolone formulation in the second quarter of 2023 and is planning to finalize the clinical program design for LGS in the second half of this year
Marinus Pharmaceuticals, Inc. - Marinus Pharmaceuticals Initiates . . . The Marinus Access Program enables physicians to request ZTALMY ® (ganaxolone) oral suspension CV for eligible patients with seizures associated with CDKL5 deficiency disorder in geographies where the product is not commercially available and as supported by local regulatory requirements